Your browser doesn't support javascript.
loading
Evaluation of (177)Lu-CHX-A''-DTPA-Bevacizumab as a radioimmunotherapy agent targeting VEGF expressing cancers.
Kameswaran, Mythili; Pandey, Usha; Gamre, Naresh; Vimalnath, K V; Sarma, Haladhar Dev; Dash, Ashutosh.
Afiliação
  • Kameswaran M; Isotope Production & Applications Division, Bhabha Atomic Research Centre, Trombay, Mumbai 400085, India. Electronic address: kmythili@barc.gov.in.
  • Pandey U; Isotope Production & Applications Division, Bhabha Atomic Research Centre, Trombay, Mumbai 400085, India.
  • Gamre N; Isotope Production & Applications Division, Bhabha Atomic Research Centre, Trombay, Mumbai 400085, India.
  • Vimalnath KV; Isotope Production & Applications Division, Bhabha Atomic Research Centre, Trombay, Mumbai 400085, India.
  • Sarma HD; Radiation Biology & Health Sciences Division, Bhabha Atomic Research Centre, Trombay, Mumbai 400085, India.
  • Dash A; Isotope Production & Applications Division, Bhabha Atomic Research Centre, Trombay, Mumbai 400085, India.
Appl Radiat Isot ; 114: 196-201, 2016 08.
Article em En | MEDLINE | ID: mdl-27258216
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Radioisótopos / Radioimunoterapia / Compostos Radiofarmacêuticos / Fator A de Crescimento do Endotélio Vascular / Ácido Pentético / Bevacizumab / Lutécio Idioma: En Ano de publicação: 2016 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Radioisótopos / Radioimunoterapia / Compostos Radiofarmacêuticos / Fator A de Crescimento do Endotélio Vascular / Ácido Pentético / Bevacizumab / Lutécio Idioma: En Ano de publicação: 2016 Tipo de documento: Article